We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more call options, than puts

Call options by funds: $805K | Put options by funds: $456K

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

4% more funds holding

Funds holding: 113 → 118 (+5)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

1% less capital invested

Capital invested by funds: $216M → $213M (-$2.47M)

Holders
118
Holders Change
+5
Holders Change %
+4.42%
% of All Funds
1.86%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
38
Reduced
25
Closed
17
Calls
$805K
Puts
$456K
Net Calls
+$349K
Net Calls Change
+$956K

Top Buyers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
+$1M
2
Millennium Management
Millennium Management
New York
+$950K
3
Citadel Advisors
Citadel Advisors
Florida
+$883K
4
Renaissance Technologies
Renaissance Technologies
New York
+$768K
5
HS
HighVista Strategies
Massachusetts
+$653K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.3M
2
SCM
Stonepine Capital Management
Oregon
-$1.01M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$663K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$361K
5
NCM
Nantahala Capital Management
Connecticut
-$334K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Sio Capital Management
New York
$1.75M – – –
VVM
27
Versant Venture Management
California
$1.69M – – –
Renaissance Technologies
28
Renaissance Technologies
New York
$1.43M +$768K +243,915 +113%
PPA
29
Parametric Portfolio Associates
Washington
$1.04M +$301K +95,698 +40%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$965K +$200K +63,494 +26%
N
31
Nuveen
North Carolina
$924K +$16.5K +5,245 +2%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$861K +$69.1K +21,961 +9%
FI
33
Fosun International
China
$819K – – –
Charles Schwab
34
Charles Schwab
California
$744K +$187K +59,256 +33%
Rockefeller Capital Management
35
Rockefeller Capital Management
New York
$707K +$1.65K +525 +0.2%
Invesco
36
Invesco
Georgia
$692K -$122K -38,712 -15%
HS
37
HighVista Strategies
Massachusetts
$645K +$653K +207,307 New
BCM
38
Bridgeway Capital Management
Texas
$602K +$472K +150,000 +345%
GCP
39
GSA Capital Partners
United Kingdom
$598K -$120K -38,014 -17%
Deutsche Bank
40
Deutsche Bank
Germany
$512K -$14.4K -4,577 -3%
CM
41
CM Management
Florida
$467K – – –
CAM
42
ClariVest Asset Management
California
$413K -$61.4K -19,500 -13%
A
43
Abingworth
United Kingdom
$406K – – –
Two Sigma Advisers
44
Two Sigma Advisers
New York
$395K -$189K -60,100 -32%
Morgan Stanley
45
Morgan Stanley
New York
$388K +$43.2K +13,720 +12%
CANY
46
Caxton Associates (New York)
New York
$367K +$371K +117,902 New
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$342K +$42.4K +13,472 +14%
AllianceBernstein
48
AllianceBernstein
Tennessee
$332K +$1.26K +400 +0.4%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$316K -$12.9K -4,107 -4%
RJA
50
Raymond James & Associates
Florida
$304K +$64K +20,337 +26%
1
2
3 4 5

CBAY Hedge Fund Activity: Q1 2022 in Review

118 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2022, worth a combined $213M — down 1.1% from $216M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CBAY positions and 17 closed out — a net gain of 5 holders — while 38 added to existing stakes and 25 trimmed.

The largest buyer was Commodore Capital, adding an estimated $1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.3M sold.

  • 118 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2022, up from 113 in Q4 2021.
  • Funds reported $213M of Cymabay Therapeutics stock for Q1 2022, down 1.1% quarter-over-quarter.
  • 22 funds opened new Cymabay Therapeutics positions in Q1 2022 and 17 closed out, a net change of +5 holders.
  • The largest Cymabay Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $1M added.
  • The largest Cymabay Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $2.3M sold.

Based on aggregated 13F filings for Q1 2022.